Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06203847

The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCA

This project is a randomized controlled clinical research design, The hypothesis P-I-C-O of the study is: For adult patients in the Taipei City and New Taipei City communities who have suffered sudden non-traumatic death and have been resuscitated by advanced paramedics, the intervention group that receives combined drug treatment (epinephrine, vasopressin, methylprednisolone) has a better rate of sustained recovery of spontaneous circulation (ROSC) (primary outcome) and long-term survival status (secondary outcomes) compared to the control group that receives single drug treatment (epinephrine).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location status: Recruiting

Location contact

Wen-Chu Chiang, MD, PhD

CONTACT

[email protected]

886-2-23123456

About this study

The global and Taiwanese survival rates for patients following an out-of-hospital cardiac arrest (OHCA) are less than 10%. The emergency medical system (EMS) plays a crucial role in patient outcomes after OHCA, providing prehospital cardiopulmonary resuscitation, defibrillation, and medication. Among these medications, the combination of epinephrine, vasopressin, and methylprednisolone holds the most potential to improve patient survival rates following OHCA.

This study aims to compare the effect of standard epinephrine therapy with a combination of epinephrine, vasopressin, and methylprednisolone administered to OHCA patients. This comparison will be made through a randomized clinical trial (RCT) within the EMS of Taipei City and New Taipei City.

Throughout the research plan, we will conduct a prehospital RCT to answer the following question (in P-I-C-O format): Will adult non-traumatic OHCA patients resuscitated by paramedics in a prehospital setting have a better chance of sustained recovery of spontaneous circulation (primary outcome), and improved survival status (secondary outcomes), if they receive combination therapy (i.e., standard doses of epinephrine, 20U of vasopressin after each dose of epinephrine up to a maximum of 80U, and one dose of 40mg methylprednisolone after the first dose of epinephrine) compared to those who receive standard doses of epinephrine? We estimate a sample size of 1,344 OHCA patients to detect a difference in the primary outcome. Based on the background data from the EMS regions under study, we expect the enrollment to take approximately 30 months to complete.

This study is referred to as the "OHCA-REVIVES" trial, which stands for A randomized clinical trial of patient outcomes following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid. The anticipated results from the "OHCA-REVIVES trial" will help determine the optimal strategy for prehospital medication, and will undoubtedly have a significant impact on resuscitation science. Through these efforts, we aim to improve the outcomes of OHCA patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (aged >= 18 )
  • Out-of-hospital cardiac arrest in the studied regions
  • Treated by paramedics authorized and capable of giving prehospital medication

Exclusion criteria

  • OHCA with traumatic etiology
  • Obvious signs of death like decapitation, rigor mortis, livor mortis, decomposition, etc.
  • DNR (Do Not Resuscitation) or termination of resuscitation requested by the family
  • Patients with known or suspected pregnancy
  • No vascular access was established before hospital arrival
  • ROSC before the administrated medication
  • No patient contact (cancelled ambulance call or the patient was transported to the hospital before the arrival of trial-trained paramedics)
  • Received epinephrine prior to the arrival of trial-trained paramedics

Treatment and study plan

Combination Group

Drug

Combination of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes, vasopressin (Pitressin® 20Unints/vial) every 3-5 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)

Standard group

Drug

standard doses of epinephrine (Adrenaline® 1mg/vial) every 3-5 minutes

Primary outcomes

  1. Rate of sustained return of spontaneous circulation (ROSC)

    Time frame: estimated 2 hours

    Return of spontaneous circulation (ROSC) is the restart of a sustained heart rhythm measured by pulsation and vital signs that permeate the body after a cardiac arrest.

    Sustained ROSC ≥ 2 hours has been used as an surrogate to survival to hospital admission in many overcrowded emergency departments (ED).

Secondary outcomes

  1. Rate of prehospital return of spontaneous circulation (ROSC)

    Time frame: estimated 1 hour

    presence of ROSC prior to arrival at emergency department (ED)

  2. Rate of survival to hospital discharge

    Time frame: estimated 30 days

    survival to hospital admission, and without in-hospital death

  3. Rate of survival with favorable neurologic status

    Time frame: estimated 30 days

    Good neurologic status (defined as Cerebral-Performance Category (CPC) score 1 and 2) at hospital discharge

Study contacts

Contact information is provided by the study sponsor or research team.

WEN CHU CHIANG, PhD

CONTACT

[email protected]

+886 926131851

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

A Randomized Clinical Trial of Patient Outcomes Following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid. (OHCA REVIVES Trial)

Acronym: REVIVES

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 12, 2024
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.